Ken Griffin Vascular Biogenics Ltd. Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.11 - $0.16 $1,148 - $1,670	10,442 Added 8.86%	128,318 $15,000
Q3 2022 Nov 14, 2022	BUY	$0.15 - $2.1 $9,171 - $128,396	61,141 Added 107.77%	117,876 $18,000
Q2 2022 Aug 15, 2022	BUY	$1.22 - $1.95 $51,775 - $82,756	42,439 Added 296.86%	56,735 $91,000
Q1 2022 May 16, 2022	SELL	$1.15 - $1.97 $22,434 - $38,430	-19,508 Reduced 57.71%	14,296 $24,000
Q4 2021 Feb 14, 2022	SELL	$1.92 - $2.53 $110,609 - $145,750	-57,609 Reduced 63.02%	33,804 $66,000
Q3 2021 Nov 15, 2021	SELL	$1.94 - $2.55 $68,361 - $89,856	-35,238 Reduced 27.82%	91,413 $187,000
Q2 2021 Aug 16, 2021	BUY	$1.69 - $2.67 $187,378 - $296,036	110,875 Added 702.81%	126,651 $302,000
Q4 2018 Feb 14, 2019	SELL	$0.6 - $1.72 $1,744 - $5,001	-2,908 Reduced 15.56%	15,776 $15,000
Q3 2018 Nov 13, 2018	BUY	$1.55 - $2.17 $4,467 - $6,253	2,882 Added 18.24%	18,684 $0
Q2 2018 Aug 10, 2018	SELL	$2.05 - $3.0 $70,837 - $103,665	-34,555 Reduced 68.62%	15,802 $0
Q1 2018 May 11, 2018	BUY	$2.27 - $8.5 $114,310 - $428,034	50,357 New	50,357 $116,000

416K

Ticker VBLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,348,896
Description
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antib...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.